Representatives of Ranbaxy Laboratories and its Japanese parent Daiichi Sankyo will jointly meet officials of the US Food and Drug Administration (USFDA) to sort out issues relating to the Indian firm's manufacturing facility at Paonta Sahib.
"Officials from Ranbaxy and Daiichi Sankyo will have a joint meeting with the USFDA this month," Daiichi Sankyo spokesperson told PTI over telephone from Tokyo.
He, however, declined to give the exact date of the meet saying, "It is not fixed yet when the meeting would take place."
The USFDA had halted review of the Paonta Sahib unit and also banned import of products manufactured at the factory.
When asked about the issues of meeting, the spokesperson said: "We have to clarify the concerns of FDA."
Some of the officials of the team formed by the Japanese firm to look into FDA's allegation would also take part in the meeting.
Daiichi Sankyo has formed a joint team with Ranbaxy to look into the USFDA's charge that the Indian drug major had falsified data and test results in its drug applications.